Overview

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arkansas
Collaborator:
Celgene Corporation
Treatments:
Thalidomide